益方生物科技（上海）股份有限公司

Chinese biopharmaceutical company founded in 2013 and headquartered in Shanghai, listed on the Shanghai STAR Market under code 688382. Discovers and develops small molecule medicines for cancer and metabolic disease, with programmes including the third generation EGFR inhibitor befotertinib developed with Betta Pharmaceuticals for non-small cell lung cancer and a URAT1 inhibitor for gout, and runs research operations in Shanghai together with an American subsidiary.